Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from oral to intravenous selexipag in stable pulmonary arterial hypertension
2016-004035-21Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of selexipag in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Safety and tolerability of switching from oral to intravenous selexipag and back and Pharmacokinetics of intravenous selexipag vs oral selexipag. Started Feb 2017; status: completed.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2016-004035-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004035-21.